What is the recommended treatment regimen for hepatitis C infection?

Hepatitis C Treatment

For most patients with chronic hepatitis C, treat with either sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks—these pangenotypic regimens achieve >95% cure rates and eliminate the need for genotyping in treatment-naïve patients without cirrhosis. 1

Treatment Algorithm by Patient Category

Non-Cirrhotic Patients (Genotypes 1a, 1b, 2,4,5,6)

Treatment-naïve OR treatment-experienced:

• Sofosbuvir/velpatasvir × 12 weeks, OR
• Glecaprevir/pibrentasvir × 8 weeks

Both options are equally effective (A1 evidence) 1

Compensated Cirrhosis (Child-Pugh A) - Genotypes 1a, 1b, 2,4,5,6

Treatment-naïve patients:

• Sofosbuvir/velpatasvir × 12 weeks, OR
• Glecaprevir/pibrentasvir × 8 weeks 1

Treatment-experienced patients:

• Sofosbuvir/velpatasvir × 12 weeks, OR
• Glecaprevir/pibrentasvir × 12 weeks (note the longer duration) 1

Genotype 3 Patients (More Complex)

Without cirrhosis:

• Treatment-naïve: Sofosbuvir/velpatasvir × 12 weeks OR glecaprevir/pibrentasvir × 8 weeks
• Treatment-experienced: Sofosbuvir/velpatasvir × 12 weeks OR glecaprevir/pibrentasvir × 12 weeks 1

With compensated cirrhosis (Child-Pugh A):

Treatment-naïve:

• Sofosbuvir/velpatasvir + ribavirin (weight-based: 1,000 mg if <75 kg, 1,200 mg if >75 kg) × 12 weeks, OR
• Sofosbuvir/velpatasvir/voxilaprevir × 12 weeks, OR
• Glecaprevir/pibrentasvir × 12 weeks 1

Treatment-experienced:

• Sofosbuvir/velpatasvir + ribavirin × 12 weeks, OR
• Sofosbuvir/velpatasvir/voxilaprevir × 12 weeks, OR
• Glecaprevir/pibrentasvir × 16 weeks 1

Decompensated Cirrhosis (Child-Pugh B or C)

Critical: Protease inhibitors are CONTRAINDICATED in decompensated cirrhosis due to substantially higher drug exposure and toxicity risk. 1, 2

Use only: Sofosbuvir/velpatasvir × 12 weeks (with or without ribavirin based on tolerance) 1

This is the treatment of choice because it avoids protease inhibitors (glecaprevir and voxilaprevir are protease inhibitors and cannot be used). The ASTRAL-4 study demonstrated safety and efficacy in Child-Pugh B patients with improvements in liver function parameters. 1

Key Clinical Considerations

When Genotyping IS Still Needed

• Prior DAA treatment failure: Genotype affects retreatment regimen selection and duration 3
• Patients from sub-Saharan Africa, China, or South-East Asia: Consider NS5A resistance testing to identify rare subtypes (1l, 4r, 3b, 3g, 6u, 6v) that may harbor resistance-associated substitutions 1

When Genotyping is NOT Needed

• Treatment-naïve patients without cirrhosis using pangenotypic regimens 3

Resistance Testing Nuance (Genotype 3 with Cirrhosis)

If NS5A resistance testing is available and shows the Y93H mutation:

• Use sofosbuvir/velpatasvir + ribavirin OR sofosbuvir/velpatasvir/voxilaprevir
• If Y93H is absent: sofosbuvir/velpatasvir alone × 12 weeks is sufficient 1

Pre-Treatment Essentials

Before initiating therapy, assess:

1. Fibrosis stage using noninvasive markers (FibroScan, APRI, FIB-4) to determine cirrhosis presence—this directly impacts regimen selection and duration 3
2. Baseline HCV RNA (quantitative) for treatment-naïve patients
3. Screen for hepatitis B and HIV co-infection 3
4. Vaccinate against hepatitis A and B if susceptible 3

Common Pitfalls to Avoid

1. Never use protease inhibitors (glecaprevir, voxilaprevir) in decompensated cirrhosis—this is an absolute contraindication 1, 2

2. Don't automatically extend treatment duration—8 weeks of glecaprevir/pibrentasvir is sufficient for most non-cirrhotic patients regardless of treatment history (except genotype 3 treatment-experienced) 1

3. Genotype 3 with cirrhosis requires special attention—don't treat with sofosbuvir/velpatasvir alone without considering ribavirin addition or using the triple regimen 1

4. Drug-drug interactions are more common with protease inhibitors (glecaprevir, voxilaprevir) compared to NS5A/NS5B inhibitors—review all medications carefully 2

5. Alcohol use is not a contraindication to treatment—ongoing alcohol use does not affect DAA efficacy in adherent patients, though abstinence counseling remains essential 3

Retreatment After DAA Failure

For patients who failed prior DAA therapy, sofosbuvir/velpatasvir/voxilaprevir achieves >95% cure rates and is the preferred rescue regimen 2, 4. Genotyping becomes important in this population to optimize regimen selection.

Special Populations

The 2023 AASLD-IDSA guidelines expanded treatment eligibility to children as young as 3 years old and provide specific recommendations for transplant recipients, HIV co-infection, and chronic kidney disease patients 5. These populations generally use the same pangenotypic regimens with duration adjustments based on individual factors.